BCAX NASDAQ
Bicara Therapeutics Inc. Common Stock
1W: +0.9%
1M: -11.8%
3M: +34.6%
YTD: +27.2%
1Y: +38.6%
$21.68
+0.84 (+4.03%)
Weekly Expected Move ±5.8%
$18
$19
$20
$21
$23
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Bullish
75
Insider+$4.8M
Congress—
ETF Holdings—
Key Statistics
Market Cap$1.2B
52W Range7.8-24.25
Volume333,148
Avg Volume579,687
Beta-0.56
Dividend—
Analyst Ratings
Company Info
CEOClaire Mazumdar Clemon
Employees55
SectorHealthcare
IndustryBiotechnology
IPO Date2024-09-13
Websitebicara.com
116 Huntington Avenue
Boston, MA 02116
US
Boston, MA 02116
US
617-468-4219
About Bicara Therapeutics Inc. Common Stock
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.
Latest News
Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC
Bicara Stock Is Up 50%, and One Biotech Investor Has Made It a 29% Portfolio Bet
Bicara (BCAX) Q1 2026 Earnings Transcript
Bicara plans Q3 alternative dosing study of ~150–200 patients as it targets mid-2027 interim analysis
Bicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Mazumdar Claire | S-Sale | 12,022 | $19.96 | 2026-05-18 |
| Mazumdar Claire | S-Sale | 2,978 | $20.35 | 2026-05-18 |
| Cohlhepp Ryan | M-Exempt | 8,000 | $3.79 | 2026-05-15 |
| Cohlhepp Ryan | S-Sale | 8,000 | $20.29 | 2026-05-15 |
| Cohlhepp Ryan | S-Sale | 4,500 | $20.29 | 2026-05-15 |